Mass tort defendants heading into the last quarter of 2026 face a docket that is bigger than ever but increasingly concentrated, and a legal landscape reshaped by one Supreme Court preemption ruling and two large settlements. The Judicial Panel on Multidistrict Litigation's September 1, 2026 pending-actions report counts 165 active MDL dockets holding 205,541 individual actions, with a handful of product cases carrying most of that weight. A mass tort is a civil action where many plaintiffs claim injury from the same product or exposure; in federal court those cases are usually consolidated before one judge as a multidistrict litigation, or MDL, for pretrial handling. The questions below cover what changed this year and what it means for a company named as a defendant, a claimant watching a settlement, or anyone trying to read the docket numbers correctly.
Table of Contents
- Where are the cases actually concentrated?
- What did Monsanto v. Durnell change for warning claims?
- The two settlements that moved in mid-2026
- Which dockets are still waiting on a trial?
- Two procedural changes defendants should track
- Frequently Asked Questions
Where are the cases actually concentrated?
The 205,541 figure describes the whole federal mass tort system, but it is not evenly spread. Johnson & Johnson's ovarian talc docket, MDL 2738 before Judge Michael Shipp in the District of New Jersey, alone held 69,250 pending actions on September 1. Bard hernia mesh, MDL 2846, held 23,316, and AFFF firefighting foam, MDL 2873, held 15,264.
That concentration matters for anyone reading headlines about "record MDL filings." Three dockets account for well over half the federal inventory. A company outside those product categories is operating in a much smaller pool, and the aggregate number tells it almost nothing about its own exposure. It also shapes judicial behavior. A transferee judge managing tens of thousands of claims runs the case differently from one managing four hundred — leadership structures are larger, census orders come earlier, and the pressure toward global resolution rather than serial trials is stronger.
What did Monsanto v. Durnell change for warning claims?
On June 25, 2026, the Supreme Court held 7–2 that the Federal Insecticide, Fungicide, and Rodenticide Act expressly preempts a state failure-to-warn claim built on the absence of a cancer warning that EPA had determined was not required. Justice Kavanaugh wrote the majority opinion in Monsanto Co. v. Durnell, reversing a $1.25 million Missouri verdict; Justices Jackson and Gorsuch dissented.
Bayer's own statement on the ruling says it "should result in the dismissal of current warnings-based claims" and foreclose future ones, and characterizes warnings-based theories as the vast majority of Roundup claims filed to date. Separately, Monsanto and class counsel proposed a nationwide class settlement for non-Hodgkin lymphoma claims in February 2026. The limit is important, and defense-side commentary has been blunt about it. A Dechert OnPoint analysis notes that Durnell reached only label-based warning claims, leaving design defect, manufacturing defect, promotional and advertising theories, and risks EPA never assessed as live avenues. The realistic expectation is amended complaints, not automatic dismissal.
The two settlements that moved in mid-2026
Johnson & Johnson disclosed an agreement with MDL 2738 plaintiff leadership for comprehensive resolution of the ovarian talc litigation. Under the terms described in the company's July 27, 2026 Form 8-K, the commitment is $5.5 billion, conditioned on at least 95% of remaining claims participating, with a first payment of no more than $3 billion in 2027 and nothing further due before 2028. In Depo-Provera MDL 3140 before Judge Casey Rodgers in the Northern District of Florida, Pfizer and plaintiffs' leadership signed a master settlement agreement on July 21, 2026. Drugwatch reports it covers roughly 80% of the 6,200-plus filed cases, and that deadlines for the December 7, 2026 Toney bellwether were vacated — before any Daubert or preemption ruling.
Terms are undisclosed. Both deals share a structural feature worth noting: resolution arrived without the causation rulings the parties had been building toward. In talc, a participation threshold does the work a verdict would have done. In Depo-Provera, the bellwether that would have tested the science came off the calendar instead.
Which dockets are still waiting on a trial?
AFFF, the firefighting foam litigation, is the clearest example of a settled half and an unsettled half. Water-provider settlements now exceed $12 billion — roughly $10.3 billion from 3M, $1.185 billion from DuPont, Chemours and Corteva, and about $315 million from BASF. No personal-injury settlement exists, and the October 2025 kidney-cancer bellwether was taken off calendar without a replacement date. Camp Lejeune is closer to a real test.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Roughly 3,600 to 3,759 Camp Lejeune Justice Act suits are pending in the Eastern District of North Carolina before four judges, and Judge Terrence Boyle has set two non-jury kidney-cancer trials: Mousser on November 9 and Fancher on November 16, 2026. Causation science is the central issue, and the Navy has received more than 400,000 administrative claims. The gap between 400,000 administrative claims and about 3,700 filed suits is the practical point for claimants. Administrative submission is a step, not a case, and the small filed population is where the law will actually be made.
Two procedural changes defendants should track
Federal Rule of Civil Procedure 16.1 took effect December 1, 2025 — the first civil rule written specifically for MDLs. It directs the transferee judge to hold an initial management conference and the parties to file a report addressing leadership, discovery, and vetting of claims. Its provisions are framed as "should," not "must," which is why practitioners remain split on whether it is a genuine change or a codification of what good judges already did.
Litigation funding disclosure is the other open question. On September 14, 2026, 214 companies filed a suggestion with the Advisory Committee on Civil Rules urging an amendment to Rule 26(a)(1)(A) that would require initial disclosure of third-party litigation funders and their agreements. The Committee's October 21, 2026 meeting is set to take up a draft uniform rule. For a defendant in an MDL right now, the practical items are short:.
- Raise Rule 16.1's claim-vetting provision at the initial conference, because its permissive wording means it will not be applied unless someone asks.
- Treat Durnell as a re-pleading event: assume design, manufacturing, and advertising theories survive and prepare for those.
- Read participation thresholds closely in any inventory deal — the J&J structure pays nothing unless 95% of remaining claims sign on.
- Watch the October 21 Advisory Committee agenda rather than the filing itself; a suggestion is the start of a multi-year rulemaking process, not a rule.
Frequently Asked Questions
Does the Durnell ruling end the Roundup litigation?
No. The Supreme Court decided only that FIFRA preempts label-based failure-to-warn claims where EPA found no warning was required. Design defect, manufacturing defect, advertising claims, and risks EPA never evaluated remain available theories, so amended complaints are the expected response.
Is the $5.5 billion talc figure a guaranteed payout?
It is a commitment conditioned on at least 95% of remaining claims participating. J&J's 8-K describes a first payment of no more than $3 billion in 2027, with nothing further due before 2028.
Why does AFFF have $12 billion in settlements but no resolution for injured people?
Those settlements are with public water providers over contamination, a separate track from personal-injury claims. The personal-injury side has no settlement, and the kidney-cancer bellwether that would have tested it was removed from the calendar in October 2025.
Does filing an administrative claim with the Navy count as a Camp Lejeune lawsuit?
No. The Navy has taken in over 400,000 administrative claims, while roughly 3,600 to 3,759 suits are actually pending in the Eastern District of North Carolina — the forum where the November 2026 kidney-cancer trials will be heard.
You Might Also Like
- Comparisons Mass Tort Litigation FAQ for September 2026: Source-Checked Answers to Common Questions
- What Is New With Defendants Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- Defendants Mass Tort Litigation 2026 Guide: eligibility, causation, and deadlines; Key Facts and Questions to Ask